HRP20220225T1 - Terlipresin za liječenje hepatorenalnog sindroma tip 1 - Google Patents

Terlipresin za liječenje hepatorenalnog sindroma tip 1 Download PDF

Info

Publication number
HRP20220225T1
HRP20220225T1 HRP20220225TT HRP20220225T HRP20220225T1 HR P20220225 T1 HRP20220225 T1 HR P20220225T1 HR P20220225T T HRP20220225T T HR P20220225TT HR P20220225 T HRP20220225 T HR P20220225T HR P20220225 T1 HRP20220225 T1 HR P20220225T1
Authority
HR
Croatia
Prior art keywords
terlipressin
patient
use according
serum creatinine
days
Prior art date
Application number
HRP20220225TT
Other languages
English (en)
Croatian (hr)
Inventor
Khurram Jamil
Stephen Chris Pappas
Jim POTENZIANO
Original Assignee
Mallinckrodt Pharmaceuticals Ireland Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Pharmaceuticals Ireland Limited filed Critical Mallinckrodt Pharmaceuticals Ireland Limited
Publication of HRP20220225T1 publication Critical patent/HRP20220225T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/0205—Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/024—Measuring pulse rate or heart rate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
    • A61B5/14542—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring blood gases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M27/00—Drainage appliance for wounds or the like, i.e. wound drains, implanted drains
    • A61M27/002—Implant devices for drainage of body fluids from one part of the body to another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/4925—Blood measuring blood gas content, e.g. O2, CO2, HCO3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/01—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
    • G01N2015/016—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N2015/1024—Counting particles by non-optical means

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Analytical Chemistry (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Surgery (AREA)
  • Medical Informatics (AREA)
  • Ecology (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
HRP20220225TT 2014-10-24 2015-10-22 Terlipresin za liječenje hepatorenalnog sindroma tip 1 HRP20220225T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462068357P 2014-10-24 2014-10-24
US201562151384P 2015-04-22 2015-04-22
EP15791430.0A EP3209317B1 (en) 2014-10-24 2015-10-22 Terlipressin for treating hepatorenal syndrome type 1
PCT/US2015/056861 WO2016065117A1 (en) 2014-10-24 2015-10-22 Method of treating patients with hepatorenal syndrome type 1

Publications (1)

Publication Number Publication Date
HRP20220225T1 true HRP20220225T1 (hr) 2022-04-29

Family

ID=54478246

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20220225TT HRP20220225T1 (hr) 2014-10-24 2015-10-22 Terlipresin za liječenje hepatorenalnog sindroma tip 1

Country Status (15)

Country Link
US (2) US10335452B2 (cg-RX-API-DMAC7.html)
EP (3) EP3978074B1 (cg-RX-API-DMAC7.html)
JP (4) JP6673915B2 (cg-RX-API-DMAC7.html)
CN (2) CN114028536B (cg-RX-API-DMAC7.html)
AU (1) AU2015335855A1 (cg-RX-API-DMAC7.html)
CA (1) CA2965325A1 (cg-RX-API-DMAC7.html)
DK (2) DK3978074T3 (cg-RX-API-DMAC7.html)
ES (2) ES2987577T3 (cg-RX-API-DMAC7.html)
FI (1) FI3978074T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20220225T1 (cg-RX-API-DMAC7.html)
HU (1) HUE058066T2 (cg-RX-API-DMAC7.html)
PL (2) PL3978074T3 (cg-RX-API-DMAC7.html)
PT (2) PT3978074T (cg-RX-API-DMAC7.html)
SI (1) SI3209317T1 (cg-RX-API-DMAC7.html)
WO (1) WO2016065117A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101814186B1 (ko) 2008-09-17 2018-03-14 키아스마 인코포레이티드 약제학적 조성물 및 연관된 투여방법
US10335452B2 (en) * 2014-10-24 2019-07-02 Mallinckrodt Hospital Products IP Limited Method of treating patients with hepatorenal syndrome type 1
US20200046798A1 (en) * 2014-10-24 2020-02-13 Mallinckrodt Hospital Products IP Limited Method of treating patients with hepatorenal syndrome type 1
US20210290725A1 (en) * 2014-10-24 2021-09-23 Mallinckrodt Pharmaceuticals Ireland Limited Method of treating patients with hepatorenal syndrome type 1
IL313083A (en) * 2016-10-21 2024-07-01 Amryt Endo Inc Terlipressin compositions and their methods of use
AU2020279395B2 (en) 2019-05-22 2025-08-28 Biovie Inc. Formulations of terlipressin
CN110251469B (zh) * 2019-07-31 2021-11-09 南京康舟医药科技有限公司 一种醋酸特利加压素制剂及其制备方法
EP4051310A1 (en) * 2019-10-30 2022-09-07 Mallinckrodt Hospital Products IP Unlimited Company Method of treating patients with hepatorenal syndrome type 1 and low mean arterial pressure
WO2023183339A1 (en) * 2022-03-22 2023-09-28 Ocelot Bio, Inc. Selective vasopressin receptor agonist for end-stage liver disease
US20240156895A1 (en) * 2022-10-28 2024-05-16 Mallinckrodt Pharmaceuticals Ireland Limited Compositions for improving kidney function in patients with hepatorenal syndrome

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1188443A1 (en) 2000-09-15 2002-03-20 Ferring BV Improved protocol for paracentesis
US7785857B2 (en) * 2006-08-31 2010-08-31 Saint Louis University Protein C variant
GB0617581D0 (en) * 2006-09-07 2006-10-18 Ucl Business Plc Biomarkers for assessing liver function
WO2008112563A1 (en) * 2007-03-09 2008-09-18 Flowmedica, Inc. Acute kidney injury treatment systems and methods
WO2009037586A2 (en) 2007-08-14 2009-03-26 Ferring B.V. Use of peptidic vasopressin receptor agonists
CN102264230B (zh) * 2008-11-10 2014-12-10 阿斯图特医药公司 用于诊断和预后肾损伤和肾衰竭的方法和组合物
CN102369296A (zh) 2009-03-09 2012-03-07 生物蛋白有限公司 Mirac蛋白
CN104434894A (zh) 2009-06-08 2015-03-25 Ucl商业有限公司 使用l-鸟氨酸苯乙酸盐治疗门静脉高压和恢复肝功能
KR20130026504A (ko) * 2010-07-14 2013-03-13 큠버랜드 에멀징 테크놀로지스 아이앤씨 트롬복산-a2 수용체 길항제를 이용한 간신증후군 및 간성뇌증의 치료방법
JP2012159356A (ja) * 2011-01-31 2012-08-23 Mochida Pharmaceut Co Ltd 敗血症診断用組合せマーカー
CN103254295A (zh) * 2013-05-31 2013-08-21 青岛国大生物制药股份有限公司 特利加压素的制备方法
US10335452B2 (en) * 2014-10-24 2019-07-02 Mallinckrodt Hospital Products IP Limited Method of treating patients with hepatorenal syndrome type 1
JP2017014206A (ja) 2015-06-30 2017-01-19 ナノアンティバイオティクス，インコーポレイテッド 腹水の治療

Also Published As

Publication number Publication date
EP3209317B1 (en) 2021-12-08
PT3978074T (pt) 2024-05-13
CN114028536B (zh) 2024-07-09
EP3978074A1 (en) 2022-04-06
JP2021155433A (ja) 2021-10-07
JP2017534618A (ja) 2017-11-24
JP6673915B2 (ja) 2020-03-25
SI3209317T1 (sl) 2022-05-31
JP2022171795A (ja) 2022-11-11
EP3209317A1 (en) 2017-08-30
DK3209317T3 (da) 2022-02-07
PT3209317T (pt) 2022-01-19
ES2987577T3 (es) 2024-11-15
US20190328831A1 (en) 2019-10-31
ES2904492T3 (es) 2022-04-05
JP6989571B2 (ja) 2022-01-05
CN107206049B (zh) 2021-12-07
US10335452B2 (en) 2019-07-02
CN114028536A (zh) 2022-02-11
PL3978074T3 (pl) 2024-08-12
CA2965325A1 (en) 2016-04-28
AU2015335855A1 (en) 2017-05-18
HUE058066T2 (hu) 2022-06-28
FI3978074T3 (fi) 2024-05-20
US20160113994A1 (en) 2016-04-28
EP3978074B1 (en) 2024-03-06
DK3978074T3 (da) 2024-05-13
JP7346494B2 (ja) 2023-09-19
EP3981420A1 (en) 2022-04-13
WO2016065117A1 (en) 2016-04-28
JP2019199485A (ja) 2019-11-21
PL3209317T3 (pl) 2022-05-23
CN107206049A (zh) 2017-09-26

Similar Documents

Publication Publication Date Title
HRP20220225T1 (hr) Terlipresin za liječenje hepatorenalnog sindroma tip 1
FI3227675T3 (fi) Aktiviini-actrii-antagonisteja ja niiden käyttöjä myelodysplastisen oireyhtymän hoitamiseksi
Warrillow et al. Preventing cerebral oedema in acute liver failure: the case for quadruple-H therapy
RU2017134443A (ru) Способ лечения с применением традипитанта
JP2017522316A5 (cg-RX-API-DMAC7.html)
HRP20240319T1 (hr) Pripravci i postupci za liječenje anemije
JP2016538277A5 (cg-RX-API-DMAC7.html)
RU2016104398A (ru) Использование антагониста vegf для лечения ретролентальной фиброплазии
RU2020125805A (ru) Способы лечения опосредованного il-6 воспаления без иммунодепрессии
RU2015134581A (ru) Доноры нитроксила с улучшенным терапевтическим индексом
Yue-Chun et al. Vagus nerve plays a pivotal role in CD4+ T cell differentiation during CVB3-induced murine acute myocarditis
JP2017534618A5 (cg-RX-API-DMAC7.html)
HRP20231469T1 (hr) Poboljšani protokol za liječenje lupus nefritisa
JP2015522015A5 (cg-RX-API-DMAC7.html)
HRP20200019T1 (hr) Terapija koja uključuje antitijela protiv klaudina 18.2 za liječenje raka
FI3215193T3 (fi) Pegyloidun interferonin annostusohjelma
Perondi et al. Double filtration plasmapheresis in the treatment of hyperproteinemia in dogs affected by Leishmania infantum
RU2010141064A (ru) Способ лечения папилломавирусных инфекций, реализуемый через индукцию интерлейкина - 18
Sołtysiak et al. Efficacy of plasma exchange in septic shock: a case report
Tobin et al. Anesthetic considerations in patients with chronic kidney disease
Gasperoni et al. MO655: Anti-Inflammatory Approach in Chronic Dialysis Patients with SARS-CoV-2: ATA or PMMA Dialyzers?
Shahdadi et al. Effect of ascending and descending stepwise dialysate flow rate profileson adequacy and complications of hemodialysis
Hinc-Kasprzyk Toxic epidermal necrolysis and multiple organ failure: case report
Ragam Adalimumab/infliximab/methotrexate
Kim et al. Interleukin-6 upregulates Th17 response via mTOR/STAT3 pathway in acute-on-chronic hepatitis B liver failure: 305